• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Welldoc Awarded 8th FDA Clearance for Bluestar Medical Device for Diabetes

by Jasmine Pennic 06/04/2020 Leave a Comment

Welldoc’s BlueStar Integration with Xealth Improves Patient Engagement by 2.5X

What You Should Know:

Marks 8th FDA clearance for BlueStar, the only reimbursable software as a medical device for diabetes that integrates with all of a patient’s existing devices.


Welldoc, revolutionizing digital health with the first FDA-cleared Software as a Medical Device (SaMD) for diabetes, announced today that the U.S. Food and Drug Administration (FDA) has cleared an additional feature for the digital health product BlueStar Rx which supports individuals using long-acting insulin. The Insulin Adjustment Program (IAP), supports the process of basal insulin titration by health care providers for adults with type 2 diabetes. Patients who are prescribed IAP as part of BlueStar, will benefit from the ease of real-time adjustments to their insulin.

BlueStar is the only FDA cleared and reimbursable Software as a Medical Device that works with a patient’s existing devices. Patients can seamlessly integrate BlueStar with blood glucose monitors, blood pressure cuffs, or fitness trackers, improving convenience and reducing out of pocket costs. BlueStar, backed by more than 45 peer-reviewed clinical posters and publications, also:

– Engages people with Type 1 and Type 2 diabetes;

– Delivers tailored, real-time feedback – 24/7, on or offline – to improve long-term health;

– Connects users with their own care team to provide new opportunities to optimize care;

– Seamlessly integrates with blood glucose meters, pharmacies, labs, activity and fitness trackers;

– Aggregates critical data to assist by delivering actionable insights to the user’s care team;

– Allows providers to use remote patient monitoring codes for reimbursement.

“With BlueStar’s Insulin Adjustment Program, a provider prescribes a safe starting dose of insulin for his or her patient, and BlueStar does the rest,” said Dr. Mansur Shomali, Welldoc’s Chief Medical Officer. “The patient no longer has to wait to talk to his or her provider to adjust the insulin. The next time the patient meets with his or her health care provider, the insulin dose has been optimized and they can spend their visit focusing on other important elements of the patient’s care.”

Tagged With: diabetes, digital health, FDA, FDA Clearance, Fitness Trackers, insulin, Medical Device, Patient Monitoring, remote patient monitoring, Type 2 Diabetes, WellDoc

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |